Medical/Pharmaceuticals APAC News & Press Release Distribution

Medical/Pharmaceuticals

All
Global

Everest Medicines Commences Operations at its mRNA Vaccine Manufacturing Facility, Accelerating Evolution to a Fully-Integrated Biopharma

--Everest owns complete pharmaceutical and vaccine value chain from discovery, clinical development, manufacturing and commercialization-- --Localizes company's mRNA vaccine production, and helps meet urgent China and global demand for innovative vaccines and medicines-- SHANGHAI, Dec. 28, 2022 ...

2022-12-28 08:00 2897

Non-invasive in vitro diagnostic (IVD) test enables early detection of colorectal cancer

SAO PAULO, Brazil, Dec. 27, 2022 /PRNewswire/ -- The DNA Methylation Detection Kit for Human SDC2, ADHFE1 and PPP2R5C Genes (Real-Time PCR), the colorectal cancer early detection product under BGI's wholly-owned subsidiary BGI Biotechnology (Wuhan) Co., Ltd., has recently obtained the medical dev...

2022-12-27 23:59 2103

Promising Singaporean Medtech Firm Osteopore Achieves Record Revenue, Enters New Markets and Operates in All Major Continents in 2022

SINGAPORE, Dec. 27, 2022 /PRNewswire/ -- Singapore-based Medtech Firm Osteopore announces their record revenue of$460,684 for Q3 CY22, an increase of 6.6% over the preceding quarter. As an extension of the same financial year, Osteopore has likewise broadened their regional operations to spanColo...

2022-12-27 20:37 3062

Brii Biosciences Provides Update on Strategic Clinical Development Progress

Topline Phase 2 data from multiple hepatitis B viral (HBV) infection functional cure combination studies expected in the first half of 2023 Initiation of Phase 2 postpartum depression (PPD) study planned for early 2023 to advance potential first-of-its-kind treatment U.S. FDA lifted clinical hol...

2022-12-27 20:00 2797

Ablaze Pharmaceuticals and Yonghe Pharma Initiate Development and Manufacturing Services Agreement for Targeted Radiopharmaceutical Therapies

SHANGHAI, Dec. 27, 2022 /PRNewswire/ -- Ablaze Pharmaceuticals ("Ablaze") announced the initiation of a development and manufacturing services agreement with Yonghe Pharmaceutical Technology Co., Ltd. ("Yonghe") to develop series of targeted radiopharmaceutical therapy ("TRT") products. Under the...

2022-12-27 10:00 2580

Hetero's 'Nirmacom' is world's first generic version of COVID-19 oral drug 'PAXLOVID' to receive WHO Prequalification

* Hetero's 'Nirmacom' (Nirmatrelvir), a generic version of Pfizer's COVID-19 oral antiviral drug 'PAXLOVID' is co-packaged with ritonavir tablets * With the launch of Nirmacom, Hetero aims to expand access of the ground-breaking antiviral in 95 LMICs including India HYDERABAD, India, Dec. 27, ...

2022-12-27 10:00 3394

MindRank Announces U.S. FDA Clearance of IND Application for MDR-001, a Novel GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes and Obesity

SHANGHAI and HANGZHOU, China, Dec. 26, 2022 /PRNewswire/ -- MindRank, an artificial intelligence (AI)-empowered drug discovery company, announces today that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application for MDR-001, an oral sma...

2022-12-26 23:00 2497

Pulnovo Medical will be attending JPM Healthcare Conference 2023

SHANGHAI, Dec. 24, 2022 /PRNewswire/ -- Pulnovo Medical Limited, a globally recognized OTM innovative platform, will be attending the upcoming 41st J.P. Morgan Healthcare Conference 2023 to discuss the latest trends in innovative technologies and development strategies in the medical device secto...

2022-12-24 20:00 3733

Fosun International Granted Three Awards from Global Banking and Finance Review in the United Kingdom

HONG KONG, Dec. 23, 2022 /PRNewswire/ -- On 23 December 2022, Fosun International was notified byGlobal Banking and Finance Review, a famous financial magazine in theUnited Kingdom, that Fosun International was granted three awards, namely "Brand of the Year Awards - Holding Group Brand of the Y...

2022-12-23 10:52 3721

JUNIPER BIOLOGICS WINS M&A AWARD 2022 BY ACQUISITION INTERNATIONAL

Best Cell & Gene Therapy Acquisition 2022: Juniper Biologics/Kolon Life Science SINGAPORE, Dec. 23, 2022 /PRNewswire/ -- Singapore-headquartered Juniper Biologics Pte Ltd , a science-led healthcare company focused on commercialising novel therapies, was awarded ...

2022-12-23 09:35 2927

Antengene Announces NDA Submission for XPOVIO® in Macau, Malaysia and Thailand for Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-cell Lymphoma

SHANGHAI and HONG KONG, Dec. 23, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hem...

2022-12-23 08:30 2832

P3 Research secures investment from Genesis Capital to accelerate expansion

* P3 is a leading New Zealand clinical trial site network founded in 1998 * With sites in seven locations throughout New Zealand, P3's clients range from large multi-nationals to small biotechs globally * Genesis Capital has become the major shareholder of the clinical trials group alongside...

2022-12-22 19:36 2880

New STIC trial data shows longer overall survival for therapy selection based on CELLSEARCH® CTC count in patients with metastatic breast cancer

Integration of CTC (Circulating Tumor Cell) enumeration* to decide between endocrine therapy and chemotherapy may lead to improved clinical outcomes and quality of life for patients with oestrogen receptor (ER) positive)/human epidermal growth factor receptor (HER) 2 negative metastatic breast ca...

2022-12-22 16:00 4008

Gemini Rosemont adds Peninsula Life Science Center eight-story office building to portfolio in all cash transaction

LOS ANGELES, Dec. 22, 2022 /PRNewswire/ -- Gemini Rosemont Commercial Real Estate, a vertically integrated real estate investment management firm specializing in Class A multi-tenant office and luxury residential properties, has acquired Peninsula Life Science Center for$59,350,000.

2022-12-22 11:27 4223

Gemini Rosemont adds Peninsula Life Science Center eight-story office building to portfolio in all cash transaction

Everest Medicines' Licensing Partner Pfizer Announces FDA and EMA Acceptance of Etrasimod Regulatory Submissions for Ulcerative Colitis

SHANGHAI, Dec. 22, 2022 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK) announced today that its licensing partner, Pfizer Inc. (NYSE: PFE) has received acceptance from the U.S. Food and Drug Administration (FDA) for review a New Drug Application (NDA) for etrasimod for individuals living with ...

2022-12-22 08:00 3357

ZIRCON Phase III Renal Cancer Study to be Presented at ASCO GU along with Theranostic Pipeline Advances

* Complete data from global Phase III ZIRCON study of Telix's investigational imaging agent TLX250-CDx in clear cell renal cell carcinoma (ccRCC) will be presented at American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium (ASCO GU) inFebruary 2023 * Telix pipeline...

2022-12-22 06:04 2179

Medidata awarded International Innovation Award for Medidata Sensor Cloud

SINGAPORE, Dec. 21, 2022 /PRNewswire/ -- For the third consecutive year, Medidata, a Dassault Systèmes company, was awarded the International Innovation Award. This year, the Medidata Sensor Cloud won the award under the Service and Solution category. Sensor Cloud provides cutting-edge data inges...

2022-12-21 14:44 2133

PeproMene Bio, Inc. Announced Complete Response of The First Patient Treated in Its B-cell Non-Hodgkin Lymphoma (B-NHL) Phase 1 Clinical Trial of PMB-CT01 (BAFFR-CAR T Cells) at City of Hope

IRVINE, Calif., Dec. 21, 2022 /PRNewswire/ -- PeproMene Bio, Inc., a clinical-stage biotech company developing novel therapies to treat cancers and immune disorders, today announced that the first patient treated in its phase 1 relapsed or refractory B-cell Non-Hodgkin Lymphoma (r/r B-NHL) clinic...

2022-12-21 09:00 1989

Ascletis' NASH Drug ASC41(THRβ) Phase II Enrollment is Progressing as Planned

HANGZHOU and SHAOXING, China, Dec. 21, 2022 /PRNewswire/ -- The enrollment of the 52-week Phase II clinical trial of thyroid hormone receptor β (THRβ) agonist ASC41 developed in house by Gannex Pharma Co., Ltd., a wholly owned subsidiary of Ascletis Pharma Inc. (HKEX: 1672, "Ascletis"), for tr...

2022-12-21 08:00 2339

Sirnaomics Announces Interim Data from Phase I Clinical Trial of RNAi Therapeutic STP707 for Treatment of Multiple Solid Tumors

First three out of five cohorts pass safety requirements, allowing the Company to dose additional cohorts to assess safety, tolerability, pharmacokinetics and anti-tumor activity HONG KONG, GERMANTOWN, Md., and SUZHOU, China, Dec. 21, 2022 /PRNewswire/ -- Sirnaomics Ltd.(Stock Code: 2257.HK) (th...

2022-12-21 00:39 2981

1 ... 97 98 99100101 102 103 ... 382